Personalized Cancer Chemotherapy - Lu, Da Yong
212,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
106 °P sammeln
  • Gebundenes Buch

Personalized Cancer Chemotherapy separately describes and addresses "individualized cancer chemotherapy" (ICC) strategies new and old, to provide readers with new insights into their characteristics and techniques, as well as key debates and future trends in this area. The book devotes chapters to drug sensitivity testing, cancer biomarkers and bioinformatics detection, pharmacogenetics, individualized antimetastatic therapy, drug combinations, assistant chemotherapy, and cost-effectiveness considerations.
A major obstacle to controlling cancer growth and metastases in patients is the…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Personalized Cancer Chemotherapy separately describes and addresses "individualized cancer chemotherapy" (ICC) strategies new and old, to provide readers with new insights into their characteristics and techniques, as well as key debates and future trends in this area. The book devotes chapters to drug sensitivity testing, cancer biomarkers and bioinformatics detection, pharmacogenetics, individualized antimetastatic therapy, drug combinations, assistant chemotherapy, and cost-effectiveness considerations.

A major obstacle to controlling cancer growth and metastases in patients is the inappropriate use of anticancer and antimetastatic drugs. Researchers and clinicians are now beginning to focus on ICC also called "personalized cancer chemotherapy" (PCC), to improve therapeutic quality and outcomes by selecting and prescribing the most appropriate and effective drugs. Using genetic, molecular, and bioinformatics data and modern experimental techniques, known tumor genes can be detected more easily than ever before; the average speed of genetic sequencing has increased 15,000 to 50,000 times since the Human Geonme Project was completed.

This book will help readers understand the pros and cons of each individualized cancer chemotherapy strategy from different angles so as to make good judgments and predictions of drug responses and clinical outcomes.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr Da Yong Lu is an associate professor at Shanghai University, PR China studying cancer pathology, biochemistry, pharmacology and clinical therapeutics, especially on the pharmacological studies of new Chinese anticancer agent probimane and MST-16 and antimetastatic targets of fibrinogen and sialic acids and individualized cancer chemotherapy (ICC) and some articles in avian flu, AIDS and neural science. His research interests are focused on the basic studies of cancer biology, pathology, treatment, origins of life and other field of science disciplines. He is as an editorial member of several reputed international journals and has also published more than 50 scientific articles in international journals.